5.79
Inventiva Adr stock is traded at $5.79, with a volume of 21,117.
It is down -1.36% in the last 24 hours and down -6.46% over the past month.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
See More
Previous Close:
$5.87
Open:
$5.69
24h Volume:
21,117
Relative Volume:
0.49
Market Cap:
$805.69M
Revenue:
$9.96M
Net Income/Loss:
$-199.33M
P/E Ratio:
-1.7374
EPS:
-3.3326
Net Cash Flow:
$-93.38M
1W Performance:
+2.12%
1M Performance:
-6.46%
6M Performance:
+96.94%
1Y Performance:
+210.46%
Inventiva Adr Stock (IVA) Company Profile
Compare IVA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IVA
Inventiva Adr
|
5.79 | 816.28M | 9.96M | -199.33M | -93.38M | -3.3326 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Inventiva Adr Stock (IVA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-03-25 | Resumed | H.C. Wainwright | Buy |
Aug-27-25 | Initiated | Piper Sandler | Overweight |
Feb-21-25 | Initiated | TD Cowen | Buy |
Nov-12-24 | Initiated | UBS | Neutral |
Oct-27-23 | Initiated | Canaccord Genuity | Buy |
May-31-23 | Initiated | ROTH MKM | Buy |
May-19-23 | Upgrade | Societe Generale | Sell → Buy |
Mar-17-23 | Initiated | Stifel | Buy |
Nov-15-22 | Downgrade | Societe Generale | Buy → Sell |
Mar-08-21 | Downgrade | Societe Generale | Buy → Sell |
Aug-05-20 | Initiated | ROTH Capital | Buy |
Aug-04-20 | Initiated | Guggenheim | Buy |
Aug-04-20 | Initiated | Stifel | Buy |
View All
Inventiva Adr Stock (IVA) Latest News
Inventiva Appoints Andrew Obenshain as Chief Executive Officer - GlobeNewswire Inc.
Inventiva (NASDAQ:IVA) Receives “Buy” Rating from Canaccord Genuity Group - Defense World
Inventiva SA Reports Progress and Challenges in 2025 - TipRanks
Inventiva (NASDAQ:IVA) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now - sharewise.com
Inventiva (NASDAQ:IVA) Shares Gap UpHere's What Happened - MarketBeat
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $14.83 Average Target Price from Analysts - Defense World
Inventiva (NASDAQ:IVA) Shares Gap DownTime to Sell? - MarketBeat
Brokerages Set Inventiva S.A. Sponsored ADR (NASDAQ:IVA) PT at $14.83 - MarketBeat
Inventiva (NASDAQ:IVA) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Sees Significant Growth in Short Interest - MarketBeat
Inventiva (IVA) to Release Quarterly Earnings on Thursday - Defense World
Inventiva (NASDAQ:IVA) Shares Gap Down – Should You Sell? - Defense World
Brokers Set Expectations for Inventiva FY2025 Earnings - MarketBeat
Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Increases By 188.0% - MarketBeat
Inventiva (NASDAQ:IVA) Shares Gap Up After Analyst Upgrade - MarketBeat
Inventiva (NASDAQ:IVA) Sees Large Volume Increase Following Analyst Upgrade - MarketBeat
Inventiva (NASDAQ:IVA) Earns Buy Rating from Analysts at HC Wainwright - Defense World
HC Wainwright Forecasts Inventiva FY2025 Earnings - Defense World
American Outdoor Brands Posts Downbeat Results, Joins Lululemon, Quanex Building And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Inventiva (NASDAQ:IVA) Shares Gap Up on Analyst Upgrade - Defense World
Inventiva (NASDAQ:IVA) Price Target Raised to $13.00 at Guggenheim - Defense World
Why Did Inventiva Stock Plunge 10.82%? - AInvest
Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s What Happened - Defense World
Inventiva (NASDAQ:IVA) Trading Up 4.3%Should You Buy? - MarketBeat
Inventiva (NASDAQ:IVA) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $10.40 Average Price Target from Brokerages - Defense World
How Much Upside is Left in Inventiva (IVA)? Wall Street Analysts Think 100.79% - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Inventiva (NASDAQ:IVA) Trading 4.3% Higher – What’s Next? - Defense World
Wealth Enhancement Advisory Services LLC Acquires New Shares in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) - Defense World
Rokmaster Resources (CVE:RKR) Stock Price Up 71.4% – Still a Buy? - Defense World
Portofino Resources (CVE:POR) Trading Up 100% – Should You Buy? - Defense World
Northern Dynasty Minerals (TSE:NDM) Stock Price Up 25% – Time to Buy? - Defense World
Northern Dynasty Minerals (TSE:NDM) Shares Up 25% – Here’s Why - Defense World
Portofino Resources (CVE:POR) Stock Price Up 100% – Time to Buy? - Defense World
Honey Badger Silver (CVE:TUF) Trading Down 12% – Here’s What Happened - Defense World
Voyageur Pharmaceuticals (CVE:VM) Trading Down 11.5% – Here’s Why - Defense World
Inventiva (NASDAQ:IVA) Trading 2.7% Higher – Here’s Why - Defense World
Inventiva (IVA) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Inventiva sets share repurchase program terms post-meeting - Investing.com
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright - TipRanks
Stifel maintains Buy on Inventiva shares with $17 target - Investing.com
Inventiva SA ADR Reports 2024 Financial Results and Strategic Updates - TipRanks
Inventiva earnings missed by $0.03, revenue topped estimates - Investing.com
Inventiva Adr Stock (IVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):